Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel

Journal of Pharmacological Sciences

Volumn 108, Issue 3, 2008, Pages 258-265

  Nomura, Hidemi ^a   Yamawaki, Hideyuki ^a   Mukohda, Masashi ^a   Okada, Muneyoshi ^a   Hara, Yukio ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Diabetes; Endothelium; Nitric oxide; Potassium channel; Smooth muscle

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 AMINOPYRIDINE; BARIUM CHLORIDE; CIMETIDINE; INDOMETACIN; INWARDLY RECTIFYING POTASSIUM CHANNEL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; POTASSIUM CHANNEL BLOCKING AGENT; TETRYLAMMONIUM; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; CHANNEL GATING; CONTROLLED STUDY; DRUG MECHANISM; MALE; NONHUMAN; RAT; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 56649120697     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08117FP     Document Type: Article

References (22)

1. Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, et al. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung. 1990;40:156-162.
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953-12956.
3. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
4. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinol. 2004;29:11-17.
5. de Rivas B, Luque M, Martell N, Fernandez C, Fernandez-Cruz A. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. J Clin Hypertens (Greenwich). 2007;9:530-537.
6. Dubey RK, Zhang HY, Reddy SR, Boegehold MA, Kotchen TA. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am J Physiol. 1993;265:R726-R732.
7. Zhang HY, Reddy SR, Kotchen TA. Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity. Hypertension. 1994;24:106-110.
8. Yoshimoto T, Naruse M, Nishikawa M, Naruse K, Tanabe A, Seki T, et al. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. Am J Physiol. 1997;272:E989-E996.
9. Yamawaki H, Sato K, Hori M, Ozaki H, Karaki H. Platelet-derived growth factor causes endothelium-independent relaxation of rabbit mesenteric artery via the release of a prostanoid. Br J Pharmacol. 2000;131:1546-1552.
10. Majithiya JB, Paramar AN, Balaraman R. Pioglitazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res. 2005;66:150-161.
11. Matsumoto T, Noguchi E, Kobayashi T, Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radic Biol Med. 2007;42:993-1007.
12. Nakamura Y, Ohya Y, Onaka U, Fujii K, Abe I, Fujishima M. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol. 1998;123:675-682.
13. Eto K, Ohya Y, Nakamura Y, Abe I, Fujishima M. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle. Eur J Pharmacol. 2001;423:1-7.
14. Heppner TJ, Bonev AD, Eckman DM, Gomez MF, Petkov GV, Nelson MT. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology. 2005;73:15-22.
15. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension. 1994;24:170-175.
16. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1-61.
17. Knock GA, Mishra SK, Aaronson PI. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol. 1999;368:103-109.
18. Peuler JD, Warfield RK, Phelps LE. Attenuation by 4-aminopyridine of delayed vasorelaxation by troglitazone. Metabolism. 2004;53:147-152.
19. Cho DH, Choi YJ, Jo SA, Jo I. Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) gamma-dependent and PPARgamma-independent signaling pathways. J Biol Chem. 2004;279:2499-2506.
20. Polikandriotis JA, Mazzella LJ, Rupnow HL, Hart CM. Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms. Arterioscler Thromb Vasc Biol. 2005;25:1810-1816.
21. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol. 2005;46:773-778.
22. Staniloae C, Mandadi V, Kurian D, Coppola J, Bernaski E, El-Khally Z, et al. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology. 2007;108:164-169.